Development of Therapeutic Cancer Vaccines Conference, 27–29 April 2003.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 648, doi. 10.1007/s00262-003-0422-7
- By:
- Publication type:
- Article
Works matching IS 03407004 AND DT 2003 AND VI 52 AND IP 10
Results: 11
1
2
Rapid turnover of the CD8<sup>+</sup>CD28<sup>-</sup> T-cell subset of effector cells in the circulation of patients with head and neck cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 599, doi. 10.1007/s00262-003-0395-6
- By:
- Publication type:
- Article
3
Tumor immunotherapy by converting tumor cells to MHC class II–positive, Ii protein–negative phenotype.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 592, doi. 10.1007/s00262-003-0404-9
- By:
- Publication type:
- Article
4
The effects of αGalCer-induced TCRVα24 Vβ11<sup>+</sup> natural killer T cells on NK cell cytotoxicity in umbilical cord blood.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 625, doi. 10.1007/s00262-003-0398-3
- By:
- Publication type:
- Article
5
Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 638, doi. 10.1007/s00262-003-0402-y
- By:
- Publication type:
- Article
6
A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 608, doi. 10.1007/s00262-003-0399-2
- By:
- Publication type:
- Article
7
Generation of non-permissive basement membranes by anti-laminin antibody fragments produced by matrix-embedded gene-modified cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 643, doi. 10.1007/s00262-003-0400-0
- By:
- Publication type:
- Article
8
Tumor mRNA–loaded dendritic cells elicit tumor-specific CD8<sup>+</sup> cytotoxic T cells in patients with malignant glioma.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 632, doi. 10.1007/s00262-003-0408-5
- By:
- Publication type:
- Article
9
Lymphocyte subsets and T<sub>h</sub>1/T<sub>h</sub>2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 617, doi. 10.1007/s00262-003-0406-7
- By:
- Publication type:
- Article
10
Optimizing dendritic cell–based anticancer immunotherapy: maturation state does have clinical impact.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 583, doi. 10.1007/s00262-003-0414-7
- By:
- Publication type:
- Article
11
Synopsis of the 5th annual Cancer Vaccines and Immunotherapy Colloquium at Walker's Cay.
- Published in:
- Cancer Immunology, Immunotherapy, 2003, v. 52, n. 10, p. 655, doi. 10.1007/s00262-003-0438-z
- By:
- Publication type:
- Article